Commercial Impacts Sample Clauses

Commercial Impacts. The Parties agree that the Contract Price will be increased by $30,023,583 in recognition of the changes listed in Section VI.B of this Change Order. The Parties agree that the Aggregate Provisional Sum will be increased by $30,023,583 in recognition of the changes listed in Section VI.B of this Change Order.
AutoNDA by SimpleDocs
Commercial Impacts. The Parties agree that the Contract Price will be increased by $1,438,830 as full compensation for all changes listed in section IX.A and IX.B of this Change Order.
Commercial Impacts. The Parties agree that the Contract Price will be decreased by $5,987,355 in recognition of the changes listed in Section III.A and III.B of this Change Order and as outlined in Exhibit F (HAZOP Actions for Phase 2). The Parties agree that the Aggregate Provisional Sum will be decreased by $10,000,000 in recognition of the changes listed in Section III.A and III.B of this Change Order and as outlined in Exhibit F (HAZOP Actions for Phase 2).
Commercial Impacts. The Parties agree that the Contract Price will be increased by $16,753 and EUR 33,000 (excludes Louisiana Sales and Use Taxes) as full compensation for all changes listed in Section V.A and V.B of this Change Order. Louisiana Sales and Use Taxes are included in Section X of this Change Order.
Commercial Impacts. The Parties agree that the Contract Price will be decreased by $127,089 (excludes Louisiana Sales and Use Taxes) as full compensation for all changes listed in Section IV.A and IV.B of this Change Order. Louisiana Sales and Use Taxes are included in Section X of this Change Order.
Commercial Impacts. In consideration of the impacts discovered during assessment of market escalation from original bid validity, Contractor agrees to offset the commercial impacts of $271,500,000.00 to its own account. The below adjustment represents the remaining impact funded by Owner. The Parties agree that the Contract Price will be increased by $101,289,000 as full compensation for all changes listed in Section IV.B of this Change Order and as outlined in Exhibit G Scope Trend #S1-0114 (Market Price Refresh).
Commercial Impacts. The Parties agree that the Contract Price will be decreased by $304,748 in recognition of the changes listed in Section X.B of this Change Order. The Parties agree that the Aggregate Provisional Sum will be decreased by $304,748 in recognition of the changes listed in Section X.B of this Change Order.
AutoNDA by SimpleDocs
Commercial Impacts. The Parties have identified the items listed in Exhibit D as requiring further evaluation to determine potential impacts to the Changed Criteria resulting from updating the Change in Law date from February 28, 2017 to December 2, 2021. The full extent of potential impacts to the Changed Criteria with respect to Exhibit D are not known at this time and are not addressed in this CO-008. Notwithstanding anything to the contrary in the Agreement or this CO-008, the Parties agree that Contractor reserves its right to address fully all potential impacts to the Changed Criteria identified in Exhibit D in a subsequent Change Order.
Commercial Impacts. The Parties agree the Contract Price includes a Provisional Sum for insurance.

Related to Commercial Impacts

  • Development and Regulatory Milestones With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT

  • Launch Customer shall use commercially reasonable efforts to begin distribution of the Google Desktop Applications promptly following the launch of the Desktop Portal.

  • Product Changes IDSI reserves the right to make design and other modifications in the Equipment at any time but shall not be obligated to implement such modifications in Equipment that has previously been delivered.

  • Commercial Milestones In partial consideration of the rights granted by AstraZeneca to Licensee hereunder, Licensee shall pay to AstraZeneca the following payments, which shall be non-refundable, non-creditable and fully earned upon the first achievement of the applicable milestone event:

  • Early Access Sublandlord agrees to cooperate with Subtenant to allow Subtenant access to the Initial Premises from the day following the Consent Date to the Delivery Date and deliver exclusive possession of the Initial Premises, including the Data Room (but excluding the Lab Space), on the Delivery Date, for design and construction purposes and for the purposes of the installation of furniture, fixtures and equipment and preparing the Initial Premises for occupancy (the “Early Access Activities”), provided that Subtenant has first given Sublandlord at least one (1) business day’s prior notice of any such access (for access prior to the Delivery Date only) and has first delivered to Sublandlord a certificate of insurance evidencing compliance with the insurance obligations herein. Such access (a) shall be solely for the Early Access Activities and not for the purposes of occupancy or possession of the Initial Premises, or of conducting business therein, and (b) shall be subject to and upon all the terms and conditions of this Sublease (including without limitation Section 11 hereof), except that Subtenant shall have no obligation to pay Base Rent or Additional Rent for the period prior to the Initial Premises Commencement Date; provided, however, that if Subtenant’s pursuit of the Early Access Activities causes an increase of more than ten percent (10%) in the cost of utilities (including without limitation water, electricity, heat or air conditioning) allocable to the Initial Premises on a square-foot basis (as compared to the average cost for such utilities over the prior three (3) months), Subtenant shall reimburse Sublandlord for such increase in the cost of utilities within thirty (30) days following Sublandlord’s presentation of an invoice therefor (including reasonable supporting documentation), which invoice shall be presented to Subtenant within fifteen (15) days following each month of such Early Access Activities. The Early Access Activities shall be performed between the hours of 6:00 a.m. and 5:00 p.m. on business days, and shall be coordinated with Sublandlord. Subtenant’s early access shall not affect or alter the Initial Premises Commencement Date, the Expansion Premises Commencement Date, the Expiration Date, or the Term.

  • Technology Access Fee In consideration of the licenses and rights granted to Regado herein, Regado shall, as of the date immediately preceding the closing (the “Closing”) of the first equity financing of Regado in which Regado is assigned a pre-money valuation of not less than [***] dollars ($[***]), issue to Archemix fully-paid and non-assessable shares of common stock of Regado equal to [***] percent ([***]%) of the total number of equity shares of Regado, on a fully diluted basis, immediately prior to the issuance of shares at the Closing. Regado shall deliver written notice of the Closing to Archemix at least [***] business days prior to such Closing in accordance with the notice provisions contained in Section 14.1 of this Agreement. Archemix and Regado shall enter into such agreements relating to the issuance of the common stock as are customary under such circumstances. For the purpose of this Agreement, “fully diluted basis” shall mean the aggregate of (a) the number of shares of common stock issued and outstanding on the determination date, (b) the number of shares of common stock issuable upon exercise, exchange or conversion of all exercisable, exchangeable or convertible securities outstanding on the determination date, assuming such securities were exercised, exchanged or converted on the determination date (without regard to whether such securities are actually exercisable, exchangeable or convertible on the determination date) and (c) the number of shares of common stock issuable pursuant to any other obligation or agreement of, or right granted by, Regado, whether vested or unvested, contingent or otherwise.

  • Project Plan Based on the Project Specifications, Omnicare CR has provided a description of services to be performed for Sponsor’s “A multi-center, randomized, double-blind, double-dummy, vehicle-controlled sequential cohort study to determine the safety of PEP005 0.025% and 0.05% topical gel in patients with actinic keratoses” (hereinafter “the Project”) and associated costs. Changes made in the Project scope, at any time during the Project, will result in a corresponding adjustment to the Project costs.

  • TIMESCALE Stage 17 may commence as soon as the *** is available from Stage 1 of the Services. Stage 17 shall be complete with the issue of the report of activities and it is estimated that this report will be issued *** from the commencement of Stage 17.

  • Protocol (cc) Part 2(b) of the ISDA Schedule – Payee Representation.

  • Development Plan As defined in Section 3.2(a).

Time is Money Join Law Insider Premium to draft better contracts faster.